Simvastatin represses protein synthesis in the muscle-derived C 2C12 cell line with a concomitant reduction in eukaryotic initiation factor 2B expression

American Journal of Physiology - Endocrinology and Metabolism

Volumn 300, Issue 3, 2011, Pages

  Tuckow, Alexander P ^a   Jefferson, Sarah J ^a   Kimball, Scot R ^a   Jefferson, Leonard S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase; Messenger RNA translation; Myoblasts; Myotubes

Indexed keywords

GUANINE NUCLEOTIDE EXCHANGE FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MESSENGER RNA; MEVALONIC ACID; PROTEASOME; SIMVASTATIN;

ARTICLE; CELL LINE; CELL STRAIN C2C12; DRUG EFFECT; MUSCLE CELL; MYOBLAST; MYOTUBE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSLATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE; CYSTEINE; EUKARYOTIC INITIATION FACTOR-2B; GUANINE NUCLEOTIDES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METHIONINE; MEVALONIC ACID; MUSCLE CELLS; MUSCLE PROTEINS; PROTEIN SYNTHESIS INHIBITORS; SIMVASTATIN;

EID: 79952157824     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00383.2010     Document Type: Article

References (44)

1. Araki M, Motojima K. Hydrophobic statins induce autophagy in cultured human rhabdomyosarcoma cells. Biochem Biophys Res Commun 367: 462-467, 2008.
2. Backes JM, Howard PA, Ruisinger JF, Moriarty PM. Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother 43: 2012-2020, 2009.
3. Balachandran S, Barber GN. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5: 51-65, 2004. (Pubitemid 38121596)
4. Cao P, Hanai J, Tanksale P, Imamura S, Sukhatme VP, Lecker SH. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J 23: 2844-2854, 2009.
5. Choi EY, Chang W, Lim S, Song BW, Cha MJ, Kim HJ, Choi E, Jang Y, Chung N, Hwang KC. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh. Eur J Pharmacol 627: 56-62, 2010.
6. Cowan JL, Morley SJ. The proteasome inhibitor, MG132, promotes the reprogramming of translation in C2C12 myoblasts and facilitates the association of hsp25 with the eIF4F complex. Eur J Biochem 271: 3596-3611, 2004. (Pubitemid 39215350)
7. Finlay GA, Malhowski AJ, Liu Y, Fanburg BL, Kwiatkowski DJ, Toksoz D. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Cancer Res 67: 9878-9886, 2007. (Pubitemid 47621236)
8. Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 145: 91-98, 1997. (Pubitemid 27294774)
9. Gallagher JW, Kubica N, Kimball SR, Jefferson LS. Reduced eukaryotic initiation factor 2Bepsilon-subunit expression suppresses the transformed phenotype of cells overexpressing the protein. Cancer Res 68: 8752-8760, 2008.
10. Grimes DS. History of the cholesterol hypothesis in Britain. QJM 102: 436-438, 2009.
11. Hanai JI, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, Lecker SH. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 117: 3940-3951, 2007. (Pubitemid 350224103)
12. Hardt SE, Tomita H, Katus HA, Sadoshima J. Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy. Circ Res 94: 926-935, 2004. (Pubitemid 38490070)
13. Hwee DT, Bodine SC. Age-related deficit in load-induced skeletal muscle growth. J Gerontol A Biol Sci Med Sci 64: 618-628, 2009.
14. Jefferson LS, Fabian JR, Kimball SR. Glycogen synthase kinase-3 is the predominant insulin-regulated eukaryotic initiation factor 2B kinase in skeletal muscle. Int J Biochem Cell Biol 31: 191-200, 1999. (Pubitemid 29094799)
15. Jiang HY, Wek RC. Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. J Biol Chem 280: 14189-14202, 2005. (Pubitemid 40517321)
16. Kimball SR, Horetsky RL, Jefferson LS. Implication of eIF2B rather than eIF4E in the regulation of global protein synthesis by amino acids in L6 myoblasts. J Biol Chem 273: 30945-30953, 1998. (Pubitemid 28533098)
17. Klein U, Ramirez MT, Kobilka BK, von Zastrow M. A novel interaction between adrenergic receptors and the alpha-subunit of eukaryotic initiation factor 2B. J Biol Chem 272: 19099-19102, 1997. (Pubitemid 27337693)
18. Kubica N, Crispino JL, Gallagher JW, Kimball SR, Jefferson LS. Activation of the mammalian target of rapamycin complex 1 is both necessary and sufficient to stimulate eukaryotic initiation factor 2Bvarepsilon mRNA translation and protein synthesis. Int J Biochem Cell Biol 40: 2522-2533, 2008.
19. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118, 2005. (Pubitemid 40261799)
20. Liao Y, Zhao H, Ogai A, Kato H, Asakura M, Kim J, Asanuma H, Minamino T, Takashima S, Kitakaze M. Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res 31: 335-344, 2008. (Pubitemid 351461114)
21. Mallinson JE, Constantin-Teodosiu D, Sidaway J, Westwood FR, Greenhaff PL. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol 587: 219-230, 2009.
22. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, Durham SK. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 131: 163-174, 1995.
23. Mira E, Manes S. Immunomodulatory and anti-inflammatory activities of statins. Endocr Metab Immune Disord Drug Targets 9: 237-247, 2009.
24. Morikawa-Futamatsu K, Adachi S, Maejima Y, Tamamori-Adachi M, Suzuki J, Kitajima S, Ito H, Isobe M. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sci 79: 1380-1390, 2006. (Pubitemid 44215930)
25. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 60: 54-61, 1996. (Pubitemid 26279221)
26. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 105: 69-76, 2010.
27. Ogura T, Tanaka Y, Nakata T, Namikawa T, Kataoka H, Ohtsubo Y. Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner. J Toxicol Sci 32: 57-67, 2007. (Pubitemid 46334070)
28. Rabkin SW, Lodha P, Kong JY. Reduction of protein synthesis and statin-induced cardiomyocyte cell death. Cardiovasc Toxicol 7: 1-9, 2007. (Pubitemid 47338489)
29. Richardson JP, Mohammad SS, Pavitt GD. Mutations causing childhood ataxia with central nervous system hypomyelination reduce eukaryotic initiation factor 2B complex formation and activity. Mol Cell Biol 24: 2352-2363, 2004. (Pubitemid 38325992)
30. Rowlands AG, Panniers R, Henshaw EC. The catalytic mechanism of guanine nucleotide exchange factor action and competitive inhibition by phosphorylated eukaryotic initiation factor 2. J Biol Chem 263: 5526-5533, 1988.
31. Santa-Catalina MO, Garcia-Marin LJ, Bragado MJ. Lovastatin effect in rat neuroblasts of the CNS: inhibition of cap-dependent translation. J Neurochem 106: 1078-1091, 2008.
32. Scorsone KA, Panniers R, Rowlands AG, Henshaw EC. Phosphorylation of eukaryotic initiation factor 2 during physiological stresses which affect protein synthesis. J Biol Chem 262: 14538-14543, 1987.
33. Skottheim IB, Gedde-Dahl A, Hejazifar S, Hoel K, Asberg A. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci 33: 317-325, 2008.
34. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 289: 1681-1690, 2003. (Pubitemid 37430274)
35. Tuckow AP, Vary TC, Kimball SR, Jefferson LS. Ectopic expression of eIF2Bε in rat skeletal muscle rescues the sepsis-induced reduction in guanine nucleotide exchange activity and protein synthesis. Am J Physiol Endocrinol Metab 299: E241-E248, 2010.
36. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 25: 2560-2566, 2005. (Pubitemid 43732279)
37. Venero CV, Thompson PD. Managing statin myopathy. Endocrinol Metab Clin North Am 38: 121-136, 2009.
38. Voisin L, Gray K, Flowers KM, Kimball SR, Jefferson LS, Vary TC. Altered expression of eukaryotic initiation factor 2B in skeletal muscle during sepsis. Am J Physiol Endocrinol Metab 270: E43-E50, 1996.
39. Wagner RJ, Martin KA, Powell RJ, Rzucidlo EM. Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR. Am J Physiol Cell Physiol 299: C119-C127, 2010.
40. Wang X, Proud CG. A novel mechanism for the control of translation initiation by amino acids, mediated by phosphorylation of eukaryotic initiation factor 2B. Mol Cell Biol 28: 1429-1442, 2008.
41. Welsh GI, Miller CM, Loughlin AJ, Price NT, Proud CG. Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 421: 125-130, 1998. (Pubitemid 28288076)
42. Williams DD, Pavitt GD, Proud CG. Characterization of the initiation factor eIF2B and its regulation in Drosophila melanogaster. J Biol Chem 276: 3733-3742, 2001.
43. Wu L, Zhao L, Zheng Q, Shang F, Wang X, Wang L, Lang B. Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes. Mol Cell Biochem 284: 65-71, 2006. (Pubitemid 44404411)
44. Yerlikaya A, Kimball SR, Stanley BA. Phosphorylation of eIF2alpha in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase. Biochem J 412: 579-588, 2008. (Pubitemid 351846423)